Joerg Reinhardt

Joerg Reinhardt is a prominent German business executive best known for his long and influential career within the global pharmaceutical industry, particularly with the Swiss healthcare giant Novartis. He has held pivotal leadership roles including serving as the Chairman of the Board of Directors of Novartis and previously as the Chief Executive Officer of its Sandoz division. His career is marked by significant contributions to corporate strategy, governance, and the expansion of generics and biosimilars businesses, alongside extensive service on the boards of other major international corporations.

Early life and education

Born in Germany in 1956, Joerg Reinhardt pursued higher education in the sciences, earning a degree in pharmacy from the University of Marburg. He furthered his academic credentials with a doctorate in pharmacology from the University of Tübingen, laying a strong scientific foundation for his future career in the pharmaceutical industry. This educational background in key life sciences provided him with deep insights into drug development and clinical research, which would prove invaluable in his subsequent executive roles.

Career at Novartis

Reinhardt began his tenure with the Ciba-Geigy corporation, which later merged with Sandoz to form Novartis in 1996. He quickly ascended through various management positions, demonstrating expertise in areas such as product development and commercial operations. A significant milestone was his appointment as the Head of Drug Development and later as the Head of Technical Operations for the entire Novartis group. From 2007 to 2010, he served as the Chief Executive Officer of the Sandoz division, where he was instrumental in driving the growth of its generics and emerging biosimilars portfolio, competing directly with firms like Teva Pharmaceutical Industries and Mylan. His strategic leadership during this period helped solidify Sandoz's position as a global leader in off-patent medicines.

Leadership roles and board memberships

In 2013, Joerg Reinhardt was elected Chairman of the Board of Directors of Novartis, succeeding Daniel Vasella. In this capacity, he has overseen a period of significant transformation for the company, including major portfolio decisions such as the multi-billion dollar asset swap with GlaxoSmithKline and the integration of AveXis for gene therapy platforms. His governance extends beyond Novartis, with notable board memberships at leading global corporations. He has served as a member of the Supervisory Board of Siemens AG, contributing to the strategic direction of the German industrial conglomerate. Furthermore, he has held a directorship at Kuehne + Nagel, one of the world's largest logistics companies, and served on the board of the Dutch chemical firm DSM.

Other professional activities and recognition

Beyond his corporate board duties, Joerg Reinhardt is actively involved in broader industry and academic initiatives. He has been associated with organizations like the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), which focuses on global health policy. His expertise is also sought in the realm of biotechnology innovation, and he has engaged with various think tanks and business forums on topics ranging from healthcare access to sustainable development. While less focused on individual awards, his recognition is reflected in his repeated inclusion in rankings of influential corporate leaders by publications like the Financial Times and his respected standing among peers at institutions such as the World Economic Forum in Davos.

Category:German businesspeople Category:1956 births Category:Living people Category:Novartis people